1 Boring Old Man » the clinical reasearch industry: the ‘atypical’ decade…

So far Eli Lilly has paid $500 M [2007] and $1.2 B [2008] to settle Zyprexa liability suits and a $1.4 B FDA [2009] fine for false advertising. AstraZeneca has paid $198 M, $350 M [2010], and $69 M [2011] to settle suits and a $520 M FDA Fine [2009]. But as has repeatedly been commented on, this is a drop in the bucket compared to their profits from world-wide sales. The standard interpretation is that these seemingly massive pay-outs are simply "the cost of doing business" and easily absorbed by the offending PHARMA manufacturers. The CROs remain largely in the background and are untouched by these penalties levied on their PHARMA employers.

via 1boringoldman.com

Posted via email from Jack's posterous